QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.108.136432v1 326/2/453    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Hollenberg, M. D. Articles by Ramachandran, R. PubMed PubMed Citation Articles by Hollenberg, M. D. Articles by Ramachandran, R.

CELLULAR AND MOLECULAR

Derivatized 2-Furoyl-LIGRLO-amide, a Versatile and Selective Probe for Proteinase-Activated Receptor 2: Binding and Visualization

Inflammation Research Network, Department of Pharmacology & Therapeutics and Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada (M.D.H., B.R., E.H., S.H., N.V., M.S., R.R.); INSERM U563, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France (N.V.); and Université Toulouse III Paul Sabatier, Toulouse, France (N.V.)

The proteinase-activated receptor-2 (PAR₂)-activating peptide with an N-terminal furoyl group modification, 2-furoyl-LIGRLO-NH₂ (2fLI), was derivatized via its free ornithine amino group to yield [³H]propionyl-2fLI and Alexa Fluor 594-2fLI that were used as receptor probes for ligand binding assays and receptor visualization both for cultured cells in vitro and for colonic epithelial cells in vivo. The binding of the radiolabeled and fluorescent PAR₂ probes was shown to be present in PAR₂-transfected Kirsten normal rat kidney cells, but not in vector-alone-transfected cells, and was abolished by pretreatment of cells with saturating concentrations of receptor-selective PAR₂ peptide agonists such as SLIGRL-NH₂ and the parent agonist 2fLI but not by reverse-sequence peptides such as 2-furoyl-OLRGIL-NH₂ that cannot activate PAR₂. The relative orders of potencies for a series of PAR₂ peptide agonists to compete for the binding of [³H]propionyl-2fLI (2fLI >> SLIGRL-NH₂ trans-cinnamoyl-LIGRLO-NH₂ > SLIGKV-NH₂ > SLIGKT-NH₂) mirrored qualitatively their relative potencies for PAR₂-mediated calcium signaling in the same cells or for vasorelaxation in a rat aorta vascular assay. In the vascular assay, the potency of Alexa Fluor 594-2fLI was the same as 2fLI. We conclude that ornithine-derivatized 2fLI peptides are conveniently synthesized PAR₂ probes that will be of value for future studies of receptor binding and visualization.

Address correspondence to: Dr. Morley D. Hollenberg, Department of Pharmacology and Therapeutics, University of Calgary Faculty of Medicine, 3330 Hospital Drive NW, Calgary, AB, Canada T2N 4N1. E-mail: mhollenb{at}ucalgary.ca